Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new ...

NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s ...

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based ...

FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, ...

Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers Early-stage NSCLC Panel - a therapy selection ...

NeoGenomics (NEO) has recently drawn investor attention without a single headline catalyst, as its share price, recent returns and current fundamentals in cancer-focused diagnostics invite closer ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics services industry, including NeoGenomics (NASDAQ:NEO) and its peers. The testing ...